These findings are consistent with recent studies that have identified a key role for ERK5 dysregulation in other cancers [6,7,8,9,10,11,19,20,39] and provides a compelling proof-of-concept rationale, together with our other data, to target ERK5 in high-grade brain tumours as means to augment the effectiveness of current temozolomide-based therapeutic strategies. This evidence concerns the gene MAPK7 and cancer.